News and Publications
Press
Deep Creek Pharma Pursuing FDA Approval for Revolutionary Treatment
Publications
Behl A, Young TM, Ma X, Cedrone E, Dobrovolskaia MA, Whitesides JF, Gmeiner WH. Activation of an adaptive antitumor immune response by the polymeric fluoropyrimidine CF10 involves TS/Top1 dual targeting. Biomed Pharmacother. 2026 Apr 21;199:119399. doi: 10.1016/j.biopha.2026.119399. [Epub ahead of print] PubMed PMID: 42019467.
Young TM, Moumouni R, Behl A, Das U, Gmeiner WH. CF10 Displays Improved Synergy with Oxaliplatin in TP53-Null and Wild-Type CRC Cells from Increased Top1cc and Replication Stress. Cancers (Basel). 2026 Mar 9;18(5). doi: 10.3390/cancers18050882. PubMed PMID: 41827815; PubMed Central PMCID: PMC12984549.
Sarkar S, Behl A, Gmeiner WH. LNP-Mediated CF10 Delivery Selectively Enhances Potency to Colorectal Cancer Cells and Preserves the TS/Top1 Dual Targeting Mechanism. ACS Appl Bio Mater. 2026 Feb 16;9(4):1989-1997. doi: 10.1021/acsabm.5c01892. Epub 2026 Feb 3. PubMed PMID: 41631794; PubMed Central PMCID: PMC13040457.
Das U, Behl A, Gmeiner WH. The fluoropyrimidine polymer CF10 synergizes with 5-ethynyl-2'-deoxyuridine by promoting telomere attrition and mitotic catastrophe. NAR Mol Med. 2026 Jan;3(1):ugag005. doi: 10.1093/narmme/ugag005. eCollection 2026 Jan. PubMed PMID: 41635782; PubMed Central PMCID: PMC12862372.
Thaker SD, Paredes J, Garai J, Martello LA, Gmeiner WH, Zabaleta J, Williams J. Colorectal Cancer: Differential Gene Expression and In Vitro Response to 5-Fluorouracil, Novel Fluoropyrimidine F10, and Potential Synergy with Lupeol. Int J Mol Sci. 2025 Nov 18;26(22). doi: 10.3390/ijms262211134. PubMed PMID: 41303616; PubMed Central PMCID: PMC12652987.
Okechukwu CC, Ma X, Li W, D'Agostino R Jr, Rees MG, Ronan MM, Roth JA, Gmeiner WH. CF10 Displayed Improved Activity Relative to 5-FU in a Mouse CRLM Model Under Conditions of Physiological Folate. Cancers (Basel). 2025 Aug 23;17(17). doi: 10.3390/cancers17172739. PubMed PMID: 40940837; PubMed Central PMCID: PMC12427396.
Okechukwu CC, Gmeiner WH. CF10/LV overcomes acquired resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axis. Cancer Drug Resist. 2025;8:35. doi: 10.20517/cdr.2025.76. eCollection 2025. PubMed PMID: 40843355; PubMed Central PMCID: PMC12367397.
Finan JM, Di Niro R, Park SY, Jeong KJ, Hedberg MD, Smith A, McCarthy GA, Haber AO, Muschler J, Sears RC, Mills GB, Gmeiner WH, Brody JR. The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Cancer Biol Ther. 2024 Dec 31;25(1):2421584. doi: 10.1080/15384047.2024.2421584. Epub 2024 Nov 8. PubMed PMID: 39513592; PubMed Central PMCID: PMC11552260.
Okechukwu CC, Ma X, Sah N, Mani C, Palle K, Gmeiner WH. Enhanced Therapeutic Efficacy of the Nanoscale Fluoropyrimidine Polymer CF10 in a Rat Colorectal Cancer Liver Metastasis Model. Cancers (Basel). 2024 Mar 30;16(7). doi: 10.3390/cancers16071360. PubMed PMID: 38611037; PubMed Central PMCID: PMC11011147.
Gmeiner WH. Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment. Cancers (Basel). 2024 Mar 2;16(5). doi: 10.3390/cancers16051029. Review. PubMed PMID: 38473386; PubMed Central PMCID: PMC10930828.
Gmeiner WH, Okechukwu CC. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. Cancer Drug Resist. 2023;6(2):257-272. doi: 10.20517/cdr.2022.136. eCollection 2023. Review. PubMed PMID: 37457133; PubMed Central PMCID: PMC10344727.
Gmeiner WH, van Waardenburg RCAM. Targeting DNA topoisomerases: past & future. Cancer Drug Resist. 2021;4:758-761. doi: 10.20517/cdr.2021.65. Epub 2021 Jul 21. PubMed PMID: 34532656; PubMed
Gmeiner WH. Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development. Onco Targets Ther. 2021;14:2121-2130. doi: 10.2147/OTT.S242224. eCollection 2021. Review. PubMed PMID: 33790575; PubMed Central PMCID: PMC8007558.
Gmeiner WH, Dominijanni A, Haber AO, Ghiraldeli LP, Caudell DL, D'Agostino R Jr, Pasche BC, Smith TL, Deng Z, Kiren S, Mani C, Palle K, Brody JR. Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties. Mol Cancer Ther. 2021 Mar;20(3):553-563. doi: 10.1158/1535-7163.MCT-20-0516. Epub 2020 Dec 23. PubMed PMID: 33361273; PubMed Central PMCID: PMC8201368.